Human Umbilical Cord Blood - Mesenchymal Stem Cells (hUCB-MSC) are free from ethical controversy which may arise during clinical and commercial development of stem cell drugs. We obtain hUCB-MSCs from the cord blood, which is regarded as medical waste despite the fact that it has been used for hematopoietic stem cell transplantation (HSCT) for over two decades. Use of cord blood has been proven to be safe with over 140,000 cases of HSCT performed world- wide without any occurrence of teratoma.

hUCB-MSCs possess excellent proliferation capacity with ability to differentiate into multiple types of cells or tissues. They are immune-privileged and thus their allogeneic use does not cause adverse immune reactions. hUCB-MSCs harvested from cord blood show the lowest levels of immunogenicity compared to those by other types of adult stem cells. In fact, instead of provoking the immunogenicity, they rather modulate the adverse immune reactions within the host and therefore making hUCB-MSCs an ideal candidate for mass-producible stem cell drug for allogeneic use.

MEDIPOST's capability for standardized processing and mass-production of hUCB-MSCs allows manufacture of "off-the-shelf" adult stem cells drugs. MEDIPOST has conducted many pre-clinical studies and clinical trials demonstrating the safety and efficacy of hUCB-MSCs as therapeutic adult stem cell drug for medicinal use.